Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    Gyongyi Szabo MD, PhD

    TitleProfessor
    InstitutionUniversity of Massachusetts Medical School
    DepartmentMedicine
    AddressUniversity of Massachusetts Medical School
    364 Plantation Street, LRB-208
    Worcester MA 01605
    Phone508-856-5275
      Other Positions
      InstitutionUMMS - Graduate School of Biomedical Sciences
      DepartmentClinical Population Health Research

      InstitutionUMMS - Graduate School of Biomedical Sciences
      DepartmentImmunology and Virology

      InstitutionUMMS - Graduate School of Biomedical Sciences
      DepartmentMD/PhD Program

      InstitutionUMMS - Programs, Centers and Institutes
      DepartmentCenter for AIDS Research

        Overview 
        Narrative

        Background

        Education:

        MD, University Medical School Debrecen, Hungary
        PhD, Hungarian Academy of Sciences (Immunology/Medicine)

        Post-Graduate Training:

        Internal Medicine Residency, University of Massachusetts Medical Center Worcester, MA

        Gastroenterology and Hepatology Fellowship, Division of Gastroenterology, University of Massachusetts Medical Center, Worcester, MA

        Current Research Activities

        Bench Research:

        Photo: Gyongyi Szabo
        1. Immune alterations induced by acute alcohol consumption: My laboratory is one of the few focusing on immunomodulation by moderate alcohol use in humans. In addition to understanding mechanisms for the increased susceptibility to infections after alcohol use, results from our investigations have relevance to decreased cardiovascular morbidity after moderate alcohol use as well as to accelerated liver disease in chronic hepatitis C virus infection. My laboratory studies changes in the interaction between accessory cells (monocytes and dendritic cells) and T lymphocytes after moderate alcohol use. The overall aim of our studies is to delineate the effect of alcohol on antigen presenting cell function and determine role of cytokine and co-stimulatory molecules leading to decreased antigen-specific T cell proliferation and impaired antimicrobial defense after alcohol use.
        2. Intracellular signaling pathways in leukocytes mediating altered cytokine production after alcohol use. We are studying intracellular signaling mechanisms leading to decreased NF- B activation in monocytic and immune cells after acute alcohol treatment in relation to signals mediated by toll-like receptors. Recent interest is to define the NF-kB-mediated intracellular mechanisms that lead to the opposite effects of acute and chronic alcohol use on pro-inflammatory cytokine production.
        3. Immune mechanisms leading to increased liver injury in HCV plus alcohol. The hypothesis is that impaired dendritic cell costimulatory activity is a pivotal defect of host response to hepatitis C infection and alcohol further reduces immunity by inhibiting maturation and functions of myeloid dendritic cells in HCV.
        4. Immunopathogenesis of liver injury in obese mice: This is a developing project to investigate the hypothesis that leptin deficient, ob/ob mice have increased susceptibility to immune-mediated liver injury in a model of Concanavalin-A or LPS-induced hepatitis. We found that in contrast to lean mice, ob/ob mice have over-activation of the NF- B signaling pathway in the liver, a mechanisms likely to contribute to increased susceptibility to liver injury. Results from these experiments have direct clinical relevance to mechanisms of liver injury in non-alcoholic steatohepatitis in human.

        Clinical Research:

        1. Immune mechanisms of increased liver injury in HCV plus alcohol: overlap with bench research project #3.
        2. Therapeutic studies in chronic hepatitis C: I am an investigator at the UMass Memorial site of the national HALT-C trial supported by NIH.
        3. Therapeutic approaches in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A clinical trial to investigate the potential therapeutic benefit of an insulin sensitizing agent in NASH is being initiated. Additional therapeutic approaches in patients with NAFLD are under development. NAFLD /NASH have recently been recognized as one of the most prevalent liver diseases in the USA, and the most common cause of cryptogenic cirrhosis.

        Research Figure

        Research Figure



        Post Docs

        Immediate opening!

        Two postdoctoral positions are available immediately to study cellular andmolecular mechanisms resulting in immunosuppression after alcohol use. Thefocus of this research is the role of monocytes and dendritic cells indecreased antigen-specific T cell activation after alcohol use.Intracellular signalling mechanisms resulting in decreased NF-kBactivation and inflammatory cytokine induction after acute alcoholconsumption are being investigated.

        Please contact Dr. Szabo for details.



        Bibliographic 
        selected publications
        List All   |   Timeline
        1. Lippai D, Bala S, Csak T, Kurt-Jones EA, Szabo G. Chronic Alcohol-Induced microRNA-155 Contributes to Neuroinflammation in a TLR4-Dependent Manner in Mice. PLoS One. 2013; 8(8):e70945.
          View in: PubMed
        2. Petrasek J, Csak T, Ganz M, Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2013 Aug; 28 Suppl 1:93-8.
          View in: PubMed
        3. Cabrera R, Szabo G. Another armed CD4(+) T cell ready to battle hepatocellular carcinoma. Hepatology. 2013 Jul; 58(1):1-3.
          View in: PubMed
        4. Szabo G, Bala S. Reply:. Hepatology. 2013 Jun; 57(6):2547.
          View in: PubMed
        5. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013 Sep; 10(9):542-52.
          View in: PubMed
        6. Zhang S, Saha B, Kodys K, Szabo G. IFN-? production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol. 2013 Sep; 59(3):442-9.
          View in: PubMed
        7. Lippai D, Bala S, Petrasek J, Csak T, Levin I, Kurt-Jones EA, Szabo G. Alcohol-induced IL-1ß in the brain is mediated by NLRP3/ASC inflammasome activation that amplifies neuroinflammation. J Leukoc Biol. 2013 Jul; 94(1):171-82.
          View in: PubMed
        8. Shukla SD, Pruett SB, Szabo G, Arteel GE. Binge ethanol and liver: new molecular developments. Alcohol Clin Exp Res. 2013 Apr; 37(4):550-7.
          View in: PubMed
        9. Zhang S, Kodys K, Babcock GJ, Szabo G. CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha. Hepatology. 2013 Sep; 58(3):940-9.
          View in: PubMed
        10. Bukong TN, Hou W, Kodys K, Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology. 2013 Jan; 57(1):70-80.
          View in: PubMed
        11. Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013; 59:155-201.
          View in: PubMed
        12. Hou W, Bukong TN, Kodys K, Szabo G. Alcohol Facilitates HCV RNA Replication Via Up-Regulation of miR-122 Expression and Inhibition of Cyclin G1 in Human Hepatoma Cells. Alcohol Clin Exp Res. 2013 Apr; 37(4):599-608.
          View in: PubMed
        13. Zhang S, Kodys K, Li K, Szabo G. Human Type 2 Myeloid Dendritic Cells Produce Interferon-? and Amplify Interferon-a in Response to Hepatitis C Virus Infection. Gastroenterology. 2013 Feb; 144(2):414-425.e7.
          View in: PubMed
        14. Szabo G, Petrasek J, Bala S. Innate immunity and alcoholic liver disease. Dig Dis. 2012; 30 Suppl 1:55-60.
          View in: PubMed
        15. Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, Szabo G. Type III Interferons, IL-28 and IL-29, Are Increased in Chronic HCV Infection and Induce Myeloid Dendritic Cell-Mediated FoxP3+ Regulatory T Cells. PLoS One. 2012; 7(10):e44915.
          View in: PubMed
        16. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012 Oct 1; 122(10):3476-89.
          View in: PubMed
        17. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS Pathog. 2012 Aug; 8(8):e1002895.
          View in: PubMed
        18. Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med. 2012; 10:151.
          View in: PubMed
        19. Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012 Nov; 56(5):1946-57.
          View in: PubMed
        20. Bala S, Tang A, Catalano D, Petrasek J, Taha O, Kodys K, Szabo G. Induction of Bcl-3 by acute binge alcohol results in Toll-like receptor 4/LPS tolerance. J Leukoc Biol. 2012 Sep; 92(3):611-20.
          View in: PubMed
        21. Szabo G, Lippai D. Molecular hepatic carcinogenesis: impact of inflammation. Dig Dis. 2012; 30(3):243-8.
          View in: PubMed
        22. Ward J, Bala S, Petrasek J, Szabo G. Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: A research study. World J Gastroenterol. 2012 Jun 14; 18(22):2798-804.
          View in: PubMed
        23. Szabo G, Csak T. Inflammasomes in liver diseases. J Hepatol. 2012 Sep; 57(3):642-54.
          View in: PubMed
        24. Szabo G, Sarnow P, Bala S. MicroRNA silencing and the development of novel therapies for liver disease. J Hepatol. 2012 Aug; 57(2):462-6.
          View in: PubMed
        25. Levin I, Petrasek J, Szabo G. The Presence of p47phox in Liver Parenchymal Cells is a Key Mediator in the Pathogenesis of Alcoholic Liver Steatosis. Alcohol Clin Exp Res. 2012 Aug; 36(8):1397-406.
          View in: PubMed
        26. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: Diverse roles in liver diseases. Hepatology. 2012 Feb; 55(2):622-33.
          View in: PubMed
        27. Bukong TN, Lo T, Szabo G, Dolganiuc A. Novel developmental biology-based protocol of embryonic stem cell differentiation to morphologically sound and functional yet immature hepatocytes. Liver Int. 2012 May; 32(5):732-41.
          View in: PubMed
        28. Bala S, Szabo G. MicroRNA Signature in Alcoholic Liver Disease. Int J Hepatol. 2012; 2012:498232.
          View in: PubMed
        29. Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: Regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology. 2011 Dec; 54(6):2185-97.
          View in: PubMed
        30. Ward J, Szabo G, McManus D, Boyer E. Advanced molecular biologic techniques in toxicologic disease. J Med Toxicol. 2011 Dec; 7(4):288-94.
          View in: PubMed
        31. Ganz M, Csak T, Nath B, Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol. 2011 Nov 21; 17(43):4772-8.
          View in: PubMed
        32. Pang M, Bala S, Kodys K, Catalano D, Szabo G. Inhibition of TLR8- and TLR4-induced Type I IFN induction by alcohol is different from its effects on inflammatory cytokine production in monocytes. BMC Immunol. 2011; 12:55.
          View in: PubMed
        33. Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 2011 Jul; 54(1):133-44.
          View in: PubMed
        34. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405.
          View in: PubMed
        35. Szabo G, Zakhari S. Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients. World J Gastroenterol. 2011 May 28; 17(20):2500-6.
          View in: PubMed
        36. Szabo G, Billiar TR, Machida K, Crispe IN, Seki E. Toll-like receptor signaling in liver diseases. Gastroenterol Res Pract. 2010; 2010:971270.
          View in: PubMed
        37. Csak T, Dolganiuc A, Kodys K, Nath B, Petrasek J, Bala S, Lippai D, Szabo G. Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. Hepatology. 2011 Jun; 53(6):1917-31.
          View in: PubMed
        38. Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K, Catalano D, Mandrekar P, Szabo G. Hepatocyte-specific hypoxia-inducible factor-1a is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology. 2011 May; 53(5):1526-37.
          View in: PubMed
        39. Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis. 2010; 28(6):737-44.
          View in: PubMed
        40. Dolganiuc A, Szabo G. Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol. 2011 Apr; 46(4):432-47.
          View in: PubMed
        41. Szabo G, Mandrekar P, Petrasek J, Catalano D. The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol Clin Exp Res. 2011 May; 35(5):782-6.
          View in: PubMed
        42. Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, Szabo G, Zakhari S. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2011 Apr; 300(4):G516-25.
          View in: PubMed
        43. Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol. 2011 Mar; 300(3):G433-41.
          View in: PubMed
        44. Petrasek J, Dolganiuc A, Csak T, Nath B, Hritz I, Kodys K, Catalano D, Kurt-Jones E, Mandrekar P, Szabo G. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology. 2011 Feb; 53(2):649-60.
          View in: PubMed
        45. Szabo G, Bakhireva LN, Savage DD. Focus on: biomarkers of fetal alcohol exposure and fetal alcohol effects. Alcohol Res Health. 2011; 34(1):56-63.
          View in: PubMed
        46. Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, Szabo G. Up-regulation of MicroRNA-155 in Macrophages Contributes to Increased Tumor Necrosis Factor {alpha} (TNF{alpha}) Production via Increased mRNA Half-life in Alcoholic Liver Disease. J Biol Chem. 2011 Jan 14; 286(2):1436-44.
          View in: PubMed
        47. Nath B, Li Y, Carroll JE, Szabo G, Tseng JF, Shah SA. Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg. 2010 Nov; 14(11):1732-41.
          View in: PubMed
        48. Petrasek J, Dolganiuc A, Csak T, Kurt-Jones EA, Szabo G. Type I Interferons Protect From Toll-Like Receptor 9-Associated Liver Injury and Regulate IL-1 Receptor Antagonist in Mice. Gastroenterology. 2011 Feb; 140(2):697-708.e4.
          View in: PubMed
        49. Petrasek J, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract. 2010; 2010.
          View in: PubMed
        50. Szabo G. The 40th anniversary of the National Institute on Alcoholism and Alcohol Abuse: the impact on liver disease. Hepatology. 2010 Jul; 52(1):10-2.
          View in: PubMed
        51. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol. 2010 Mar 21; 16(11):1321-9.
          View in: PubMed
        52. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology. 2010 Jun; 138(7):2321-31, 2331.e1-2.
          View in: PubMed
        53. Szabo G, Wands JR, Eken A, Osna NA, Weinman SA, Machida K, Joe Wang H. Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res. 2010 Oct; 34(10):1675-86.
          View in: PubMed
        54. Chang S, Kodys K, Szabo G. Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells. Hepatology. 2010 Jan; 51(1):35-42.
          View in: PubMed
        55. Szabo G, Mandrekar P. Focus on: alcohol and the liver. Alcohol Res Health. 2010; 33(1):87-96.
          View in: PubMed
        56. Bala S, Marcos M, Szabo G. Emerging role of microRNAs in liver diseases. World J Gastroenterol. 2009 Dec 7; 15(45):5633-40.
          View in: PubMed
        57. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, Thomas WD, Szabo G, Finberg RW, Ambrosino DM, Babcock GJ. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J Virol. 2009 Dec; 83(23):12473-82.
          View in: PubMed
        58. Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, Szabo G. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res. 2009 Oct; 33(10):1704-10.
          View in: PubMed
        59. Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G. The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol. 2009 Jul 15; 183(2):1320-7.
          View in: PubMed
        60. Nath B, Szabo G. Alcohol-induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: implications for immunity. Semin Liver Dis. 2009 May; 29(2):166-77.
          View in: PubMed
        61. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol. 2009 Jun; 50(6):1258-66.
          View in: PubMed
        62. Dolganiuc A, Szabo G. In vitro and in vivo models of acute alcohol exposure. World J Gastroenterol. 2009 Mar 14; 15(10):1168-77.
          View in: PubMed
        63. Velayudham A, Dolganiuc A, Ellis M, Petrasek J, Kodys K, Mandrekar P, Szabo G. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009 Mar; 49(3):989-97.
          View in: PubMed
        64. Szabo G. The "health" and future of the physician-scientist in hepatology. Hepatology. 2009 Feb; 49(2):341-3.
          View in: PubMed
        65. Lau AH, Szabo G, Thomson AW. Antigen-presenting cells under the influence of alcohol. Trends Immunol. 2009 Jan; 30(1):13-22.
          View in: PubMed
        66. Szabo G, Mandrekar P. A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res. 2009 Feb; 33(2):220-32.
          View in: PubMed
        67. Hritz I, Velayudham A, Dolganiuc A, Kodys K, Mandrekar P, Kurt-Jones E, Szabo G. Bone marrow-derived immune cells mediate sensitization to liver injury in a myeloid differentiation factor 88-dependent fashion. Hepatology. 2008 Oct; 48(4):1342-7.
          View in: PubMed
        68. Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, Kurt-Jones E, Szabo G. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology. 2008 Oct; 48(4):1224-31.
          View in: PubMed
        69. Dolganiuc A, Paek E, Kodys K, Thomas J, Szabo G. Myeloid dendritic cells of patients with chronic HCV infection induce proliferation of regulatory T lymphocytes. Gastroenterology. 2008 Dec; 135(6):2119-27.
          View in: PubMed
        70. Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis. 2008 Aug; 12(3):675-92, x.
          View in: PubMed
        71. Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes. Alcohol Clin Exp Res. 2008 Sep; 32(9):1565-73.
          View in: PubMed
        72. Dolganiuc A, Szabo G. T cells with regulatory activity in hepatitis C virus infection: what we know and what we don't. J Leukoc Biol. 2008 Sep; 84(3):614-22.
          View in: PubMed
        73. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb; 47(2):605-12.
          View in: PubMed
        74. Szabo G, Mandrekar P. Human monocytes, macrophages, and dendritic cells: alcohol treatment methods. Methods Mol Biol. 2008; 447:113-24.
          View in: PubMed
        75. Szabo G, Dolganiuc A. The role of plasmacytoid dendritic cell-derived IFN alpha in antiviral immunity. Crit Rev Immunol. 2008; 28(1):61-94.
          View in: PubMed
        76. Szabo G, Dolganiuc A. Hepatitis C core protein - the "core" of immune deception? J Hepatol. 2008 Jan; 48(1):8-11.
          View in: PubMed
        77. Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007 Nov; 27(4):339-50.
          View in: PubMed
        78. Szabo G, Chang S, Dolganiuc A. Altered innate immunity in chronic hepatitis C infection: cause or effect? Hepatology. 2007 Oct; 46(4):1279-90.
          View in: PubMed
        79. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, Szabo G. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology. 2007 Nov; 133(5):1627-36.
          View in: PubMed
        80. Chang S, Dolganiuc A, Szabo G. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol. 2007 Sep; 82(3):479-87.
          View in: PubMed
        81. Szabo G, Mandrekar P, Oak S, Mayerle J. Effect of ethanol on inflammatory responses. Implications for pancreatitis. Pancreatology. 2007; 7(2-3):115-23.
          View in: PubMed
        82. Mandrekar P, Jeliazkova V, Catalano D, Szabo G. Acute alcohol exposure exerts anti-inflammatory effects by inhibiting IkappaB kinase activity and p65 phosphorylation in human monocytes. J Immunol. 2007 Jun 15; 178(12):7686-93.
          View in: PubMed
        83. Norkina O, Dolganiuc A, Shapiro T, Kodys K, Mandrekar P, Szabo G. Acute alcohol activates STAT3, AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes. J Leukoc Biol. 2007 Sep; 82(3):752-62.
          View in: PubMed
        84. Davis GL, Krawczynski K, Szabo G. Hepatitis C virus infection--pathobiology and implications for new therapeutic options. Dig Dis Sci. 2007 Apr; 52(4):857-75.
          View in: PubMed
        85. Szabo G, Dolganiuc A, Dai Q, Pruett SB. TLR4, ethanol, and lipid rafts: a new mechanism of ethanol action with implications for other receptor-mediated effects. J Immunol. 2007 Feb 1; 178(3):1243-9.
          View in: PubMed
        86. Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, Szabo G. Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol. 2006 Nov 15; 177(10):6758-68.
          View in: PubMed
        87. Szabo G, Dolganiuc A. HCV immunopathogenesis: virus-induced strategies against host immunity. Clin Liver Dis. 2006 Nov; 10(4):753-71.
          View in: PubMed
        88. Brown LA, Cook RT, Jerrells TR, Kolls JK, Nagy LE, Szabo G, Wands JR, Kovacs EJ. Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res. 2006 Sep; 30(9):1624-31.
          View in: PubMed
        89. Drechsler Y, Dolganiuc A, Norkina O, Romics L, Li W, Kodys K, Bach FH, Mandrekar P, Szabo G. Heme oxygenase-1 mediates the anti-inflammatory effects of acute alcohol on IL-10 induction involving p38 MAPK activation in monocytes. J Immunol. 2006 Aug 15; 177(4):2592-600.
          View in: PubMed
        90. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology. 2006 Aug; 44(2):287-98.
          View in: PubMed
        91. Velayudham A, Hritz I, Dolganiuc A, Mandrekar P, Kurt-Jones E, Szabo G. Critical role of toll-like receptors and the common TLR adaptor, MyD88, in induction of granulomas and liver injury. J Hepatol. 2006 Dec; 45(6):813-24.
          View in: PubMed
        92. Oak S, Mandrekar P, Catalano D, Kodys K, Szabo G. TLR2- and TLR4-mediated signals determine attenuation or augmentation of inflammation by acute alcohol in monocytes. J Immunol. 2006 Jun 15; 176(12):7628-35.
          View in: PubMed
        93. Romics L, Szabo G, Coffey JC, Wang JH, Redmond HP. The emerging role of toll-like receptor pathways in surgical diseases. Arch Surg. 2006 Jun; 141(6):595-601.
          View in: PubMed
        94. Spies C, Eggers V, Szabo G, Lau A, von Dossow V, Schoenfeld H, Althoff H, Hegenscheid K, Bohm B, Schroeder T, Pfeiffer S, Ziemer S, Paschen C, Klein M, Marks C, Miller P, Sander M, Wernecke KD, Achterberg E, Kaisers U, Volk HD. Intervention at the level of the neuroendocrine-immune axis and postoperative pneumonia rate in long-term alcoholics. Am J Respir Crit Care Med. 2006 Aug 15; 174(4):408-14.
          View in: PubMed
        95. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res. 2006 Apr; 30(4):709-19.
          View in: PubMed
        96. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res. 2006 Apr; 30(4):720-30.
          View in: PubMed
        97. Szabo G. Hepatitis C virus NS5A protein--a master regulator? Gastroenterology. 2006 Mar; 130(3):995-9.
          View in: PubMed
        98. Dolganiuc A, Garcia C, Kodys K, Szabo G. Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection. World J Gastroenterol. 2006 Feb 28; 12(8):1198-204.
          View in: PubMed
        99. Dolganiuc A, Bakis G, Kodys K, Mandrekar P, Szabo G. Acute ethanol treatment modulates Toll-like receptor-4 association with lipid rafts. Alcohol Clin Exp Res. 2006 Jan; 30(1):76-85.
          View in: PubMed
        100. Mandrekar P, Catalano D, White B, Szabo G. Moderate alcohol intake in humans attenuates monocyte inflammatory responses: inhibition of nuclear regulatory factor kappa B and induction of interleukin 10. Alcohol Clin Exp Res. 2006 Jan; 30(1):135-9.
          View in: PubMed
        101. Szabo G, Velayudham A, Romics L, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res. 2005 Nov; 29(11 Suppl):140S-145S.
          View in: PubMed
        102. Romics L, Dolganiuc A, Velayudham A, Kodys K, Mandrekar P, Golenbock D, Kurt-Jones E, Szabo G. Toll-like receptor 2 mediates inflammatory cytokine induction but not sensitization for liver injury by Propioni- bacterium acnes. J Leukoc Biol. 2005 Dec; 78(6):1255-64.
          View in: PubMed
        103. Mandrekar P, Pruett S, Arteel G, Thiele G, Szabo G. RSA 2004: combined basic research satellite symposium - session two: toll-like receptors and organ damage. Alcohol Clin Exp Res. 2005 Sep; 29(9):1744-8.
          View in: PubMed
        104. Szabo G, Hoek JB, Darley-Usmar V, Hajnoczky G, Knudsen T, Mochly-Rosen D, Zakhari S. RSA 2004: combined basic research satellite symposium - session three: alcohol and mitochondrial metabolism: at the crossroads of life and death. Alcohol Clin Exp Res. 2005 Sep; 29(9):1749-52.
          View in: PubMed
        105. Szabo G, Weinman SA, Gao B, Polyak SJ, Mandrekar P, Thiele GM. RSA 2004: combined basic research satellite symposium - session four: hepatitis virus and alcohol interactions in immunity and liver disease. Alcohol Clin Exp Res. 2005 Sep; 29(9):1753-7.
          View in: PubMed
        106. Romics L, Mandrekar P, Kodys K, Velayudham A, Drechsler Y, Dolganiuc A, Szabo G. Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. Alcohol Clin Exp Res. 2005 Jun; 29(6):1018-26.
          View in: PubMed
        107. Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology. 2005; 210(2-4):237-47.
          View in: PubMed
        108. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 2004 Nov; 127(5):1513-24.
          View in: PubMed
        109. Mandrekar P, Catalano D, Dolganiuc A, Kodys K, Szabo G. Inhibition of myeloid dendritic cell accessory cell function and induction of T cell anergy by alcohol correlates with decreased IL-12 production. J Immunol. 2004 Sep 1; 173(5):3398-407.
          View in: PubMed
        110. Romics L, Dolganiuc A, Kodys K, Drechsler Y, Oak S, Velayudham A, Mandrekar P, Szabo G. Selective priming to Toll-like receptor 4 (TLR4), not TLR2, ligands by P. acnes involves up-regulation of MD-2 in mice. Hepatology. 2004 Sep; 40(3):555-64.
          View in: PubMed
        111. Romics L, Kodys K, Dolganiuc A, Graham L, Velayudham A, Mandrekar P, Szabo G. Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver. Hepatology. 2004 Aug; 40(2):376-85.
          View in: PubMed
        112. Szabo G, Dolganiuc A, Mandrekar P, White B. Inhibition of antigen-presenting cell functions by alcohol: implications for hepatitis C virus infection. Alcohol. 2004 Jul; 33(3):241-9.
          View in: PubMed
        113. Szabo G, Catalano D, White B, Mandrekar P. Acute alcohol consumption inhibits accessory cell function of monocytes and dendritic cells. Alcohol Clin Exp Res. 2004 May; 28(5):824-8.
          View in: PubMed
        114. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L, Mandrekar P, Zapp M, Szabo G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol. 2003 Jun 1; 170(11):5615-24.
          View in: PubMed
        115. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Mandrekar P, Szabo G. Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. Alcohol Clin Exp Res. 2003 Jun; 27(6):1023-31.
          View in: PubMed
        116. Szabo G. Pathogenic interactions between alcohol and hepatitis C. Curr Gastroenterol Rep. 2003 Feb; 5(1):86-92.
          View in: PubMed
        117. Thiele GM, Szabo G, Kovacs EJ, Bautista AP, Sosa L, Jerrells TR. Modulation of immunity and viral-host interactions by alcohol. Alcohol Clin Exp Res. 2002 Dec; 26(12):1897-908.
          View in: PubMed
        118. Mandrekar P, Bellerose G, Szabo G. Inhibition of NF-kappa B binding correlates with increased nuclear glucocorticoid receptor levels in acute alcohol-treated human monocytes. Alcohol Clin Exp Res. 2002 Dec; 26(12):1872-9.
          View in: PubMed
        119. Mandrekar P, Dolganiuc A, Bellerose G, Kodys K, Romics L, Nizamani R, Szabo G. Acute alcohol inhibits the induction of nuclear regulatory factor kappa B activation through CD14/toll-like receptor 4, interleukin-1, and tumor necrosis factor receptors: a common mechanism independent of inhibitory kappa B alpha degradation? Alcohol Clin Exp Res. 2002 Nov; 26(11):1609-14.
          View in: PubMed
        120. Szabo G, Romics L, Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis. 2002 Nov; 6(4):1045-66, x.
          View in: PubMed
        121. Drechsler Y, Chavan S, Catalano D, Mandrekar P, Szabo G. FcgammaR cross-linking mediates NF-kappaB activation, reduced antigen presentation capacity, and decreased IL-12 production in monocytes without modulation of myeloid dendritic cell development. J Leukoc Biol. 2002 Oct; 72(4):657-67.
          View in: PubMed
        122. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci. 2002 Jul; 47(7):1632-7.
          View in: PubMed
        123. Szabo G, Mandrekar P. Ethanol-mediated regulation of transcription factors in immunocompetent cells. Front Biosci. 2002 May 1; 7:a80-9.
          View in: PubMed
        124. Szabo G, Mandrekar P, Dolganiuc A, Catalano D, Kodys K. Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels. Alcohol Clin Exp Res. 2001 Dec; 25(12):1766-72.
          View in: PubMed
        125. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med. 2001 Sep; 49(5):442-9.
          View in: PubMed
        126. Szabo G, Catalano D, Bellerose G, Mandrekar P. Interferon alpha and alcohol augment nuclear regulatory factor-kappaB activation in HepG2 cells, and interferon alpha increases pro-inflammatory cytokine production. Alcohol Clin Exp Res. 2001 Aug; 25(8):1188-97.
          View in: PubMed
        127. Browne TR, Szabo GK, Leppik IE, Josephs E, Paz J, Baltes E, Jensen CM. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol. 2000 Jun; 40(6):590-5.
          View in: PubMed
        128. Browne TR, Szabo GK, Ajami A, Browne DG. Performance of human mass balance studies with stable isotope-labeled drug and continuous flow-isotope ratio mass spectrometry: a progress report. J Clin Pharmacol. 1998 Apr; 38(4):309-14.
          View in: PubMed
        129. Durso R, Evans JE, Josephs E, Szabo GK, Evans BA, Handler JS, Jennings D, Browne TR. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa. Ann Neurol. 1997 Sep; 42(3):300-4.
          View in: PubMed
        130. Browne TR, Szabo GK, Davoudi H, Josephs EG. Determination of pharmacokinetic drug interactions with carbamazepine and phenytoin using stable isotope labeling and simple high-performance liquid chromatography/ultraviolet detection technique. Neurology. 1994 Dec; 44(12):2410-1.
          View in: PubMed
        131. Szabo GK, Browne HK, Ajami A, Josephs EG. Alternatives to least squares linear regression analysis for computation of standard curves for quantitation by high performance liquid chromatography: applications to clinical pharmacology. J Clin Pharmacol. 1994 Mar; 34(3):242-9.
          View in: PubMed
        132. Browne TR, Szabo GK, Ajami A, Wagner D. Performance of human mass balance/metabolite identification studies using stable isotope (13C, 15N) labeling and continuous-flow isotope-ratio mass spectrometry as an alternative to radioactive labeling methods. J Clin Pharmacol. 1993 Mar; 33(3):246-52.
          View in: PubMed
        133. Browne TR, Szabo GK, McEntegart C, Evans JE, Evans BA, Miceli JJ, Quon C, Dougherty CL, Kres J, Davoudi H. Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique. J Clin Pharmacol. 1993 Jan; 33(1):89-94.
          View in: PubMed
        134. Browne TR, Szabo GK, Schumacher GE, Greenblatt DJ, Evans JE, Evans BA. Bioavailability studies of drugs with nonlinear pharmacokinetics: I. Tracer dose AUC varies directly with serum concentration. J Clin Pharmacol. 1992 Dec; 32(12):1141-5.
          View in: PubMed
        135. Galpern WR, Miller LG, Greenblatt DJ, Szabo GK, Browne TR, Shader RI. Chronic benzodiazepine administration. IX. Attenuation of alprazolam discontinuation effects by carbamazepine. Biochem Pharmacol. 1991 Dec 11; 42 Suppl:S99-104.
          View in: PubMed
        136. Browne TR, Szabo GK. New pharmacokinetic methods for the study of antiepileptic medications of the 1990s. Epilepsia. 1991; 32 Suppl 5:S66-73.
          View in: PubMed
        137. Szabo GK, Pylilo RJ, Davoudi H, Browne TR. Simultaneous determination of p-hydroxylated and dihydrodiol metabolites of phenytoin in urine by high-performance liquid chromatography. J Chromatogr. 1990 Dec 28; 535(1-2):279-85.
          View in: PubMed
        138. Szabo GK, Pylilo RJ, Perchalski RJ, Browne TR. Simultaneous separation and determination (in serum) of phenytoin and carbamazepine and their deuterated analogues by high-performance liquid chromatography--ultraviolet detection for tracer studies. J Chromatogr. 1990 Dec 28; 535(1-2):271-7.
          View in: PubMed
        139. Browne TR, Greenblatt DJ, Schumacher GE, Szabo GK, Evans JE, Evans BA. New pharmacokinetic methods. III. Two simple test for "deep pool effect". J Clin Pharmacol. 1990 Aug; 30(8):680-5.
          View in: PubMed
        140. Browne TR, Szabo GK, Walsh CT, Schumacher GE, Evans JE, Evans BA. New pharmacokinetic methods. II: Determination of the presence or absence of product inhibition in drugs with nonlinear pharmacokinetics. J Clin Pharmacol. 1990 Jul; 30(7):578-84.
          View in: PubMed
        141. Browne TR, Greenblatt DJ, Szabo GK, Evans JE, Evans BA. New pharmacokinetic methods: I. Estimation of mean serum concentration from trough serum concentration. J Clin Pharmacol. 1990 Jun; 30(6):482-8.
          View in: PubMed
        142. Browne TR, Szabo GK. A pharmacokinetic rationale for three times daily administration of ethotoin (Peganone). J Clin Pharmacol. 1989 Mar; 29(3):270-1.
          View in: PubMed
        143. Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Miketta RM, Sherry KM, Szabo GK. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol. 1989; 27 Suppl 1:95S-100S.
          View in: PubMed
        144. Mikati MA, Szabo GK, Pylilo RJ, LeDuc BW, Browne TR, Greenblatt DJ. Improved high-performance liquid chromatographic assay of antipyrine, hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine in urine. J Chromatogr. 1988 Dec 9; 433:305-11.
          View in: PubMed
        145. Szabo GK, Davoudi H, Durso R. High-performance liquid chromatographic method for measuring homovanillic acid in cerebrospinal fluid using electrochemical detection with internal standardization. J Chromatogr. 1988 Aug 19; 430(1):112-7.
          View in: PubMed
        146. Browne TR, Szabo GK, Evans JE, Evans BA, Greenblatt DJ, Mikati MA. Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance. Neurology. 1988 Jul; 38(7):1146-50.
          View in: PubMed
        147. Browne TR, Szabo GK, Evans J, Evans BA, Greenblatt DJ, Mikati MA. Phenobarbital does not alter phenytoin steady-state serum concentration or pharmacokinetics. Neurology. 1988 Apr; 38(4):639-42.
          View in: PubMed
        148. Browne TR, Greenblatt DJ, Evans JE, Szabo GK, Evans BA, Schumacher GE. Estimation of the elimination half-life of a drug at any serum concentration when the Km and Vmax of the drug are known: calculations and validation with phenytoin. J Clin Pharmacol. 1987 Apr; 27(4):318-20.
          View in: PubMed
        149. Browne TR, Greenblatt D, Evans JE, Evans BA, Szabo GK, Schumacher GE. Determination of the in vivo Km and Vmax of a drug with tracer studies. J Clin Pharmacol. 1987 Apr; 27(4):321-4.
          View in: PubMed
        150. Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Napoliello MJ, Sherry KM, Szabo GK. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology. 1987 Feb; 37(2):184-9.
          View in: PubMed
        151. Szabo GK, Browne TR. Mass spectrometry: preparation of biologic specimens. J Clin Pharmacol. 1986 Jul-Aug; 26(6):400-5.
          View in: PubMed
        152. Browne TR, Evans JE, Kasdon DL, Szabo GK, Evans BA, Greenblatt DJ. Distribution. J Clin Pharmacol. 1986 Jul-Aug; 26(6):425-6.
          View in: PubMed
        153. Browne TR, Greenblatt DJ, Evans JE, Szabo GK, Evans BA, Schumacher GE. Pharmacokinetics: dose-dependent changes. J Clin Pharmacol. 1986 Jul-Aug; 26(6):463-8.
          View in: PubMed
        154. Evans JE, Browne TR, Kasdon DL, Szabo GK, Evans BA, Greenblatt DJ. Staggered stable isotope administration technique for study of drug distribution. J Clin Pharmacol. 1985 May-Jun; 25(4):309-12.
          View in: PubMed
        155. Browne TR, Greenblatt DJ, Harmatz JS, Evans JE, Szabo GK, Evans BA, Schumacher GE. Studies with stable isotopes III: Pharmacokinetics of tracer doses of drug. J Clin Pharmacol. 1985 Jan-Feb; 25(1):59-63.
          View in: PubMed
        156. Browne TR, Evans JE, Szabo GK, Evans BA, Greenblatt DJ, Schumacher GE. Studies with stable isotopes I: Changes in phenytoin pharmacokinetics and biotransformation during monotherapy. J Clin Pharmacol. 1985 Jan-Feb; 25(1):43-50.
          View in: PubMed
        157. Browne TR, Evans JE, Szabo GK, Evans BA, Greenblatt DJ. Studies with stable isotopes II: Phenobarbital pharmacokinetics during monotherapy. J Clin Pharmacol. 1985 Jan-Feb; 25(1):51-8.
          View in: PubMed
        158. Browne TR, Feldman RG, Buchanan RA, Allen NC, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983 Apr; 33(4):414-8.
          View in: PubMed
        159. Szabo GK, Browne TR. Improved isocratic liquid-chromatographic simultaneous measurement of phenytoin, phenobarbital, primidone, carbamazepine, ethosuximide, and N-desmethylmethsuximide in serum. Clin Chem. 1982 Jan; 28(1):100-4.
          View in: PubMed
        For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
        Gyongyi's Networks
        Click the "See All" links for more information and interactive visualizations!
        Concepts
        _
        Co-Authors
        _
        Similar People
        _
        Same Department
        Physical Neighbors
        _

        This is an official Page/Publication of the University of Massachusetts Worcester Campus
        Office of the Vice Provost for Research, 55 Lake Ave North, Worcester, Massachusetts 01655
        Questions or Comments? Email: publicaffairs@umassmed.edu Phone: 508-856-1572